Member Info for HereforHemo

Quote from early June:

"With mining now underway and ore sales to the DMS plant set to commence, we are well positioned to ramp up production and meet growing demand. These developments reflect the success of our strategic investment and development initiatives, which are now delivering tangible, value-accretive results"

With production ramping up to 20,000 tons of unweathered magnetite ore per month and a second larger ball mill fully funded to increase capacity to meet the demand from larger offtakers, this to me has to be worth many multiples of the current value.

It's obviously a waiting game for news but I feel the plant and infrastructure alone is worth 3/4 times their current value, and with revenue and profitability on the horizon its definitely a hold and accumulate in my view.

Well I don’t agree with the negativity and also trying to chart an AIM stock, complete waste of time imo.

Since their first blast there’s absolutely no reason why they wouldn’t start putting out production updates in the very near future and also enlightening us on the bigger mill acquisition and new offtake partners.

An II might be offloading but it’ll bounce back soon enough. Imo anyway.

I'm expecting positive updates very soon. Just a waiting game before this rerates as far as I'm concerned.

Kris Andersson, CEO of Ironveld, commented:

"I am very pleased with the progress being made on the ground. We are now entering a pivotal phase as we transition into revenue generation, with sales of our DMS-grade magnetite, under the existing offtake agreement with Sable Platinum Pty Ltd., expected to commence shortly. Encouragingly, demand for our material has exceeded expectations, with new enquiries and requests for product coming in on a consistent basis.

"The emerging opportunity to sell ore directly adds an exciting dimension to our revenue streams and further reinforces the international demand for vanadium, titanium, and iron. This is particularly promising for our future smelting operations, which are expected to deliver high-margin products and play a central role in unlocking the full value of our asset base.

"Over the coming months, we anticipate a fundamental shift in Ironveld's trajectory, from a development-stage company to a fully operational, revenue-generating business with positive cash flow. It is an exceptionally exciting time for the Company, and the team and I remain fully committed to executing our strategy and delivering long-term value for our shareholders."

Updates to come on the acquisition of the new ball mill, the revised production targets that will allow, new offtake agreements and how production is going at the moment.

A lot to look forward to next month.

https://m.miningweekly.com/article/ironveld-achieves-first-blast-at-lapon-2025-06-06

Well they said the waste removal would take a week:‘Over the coming week, the overlying Gabro Norite waste rock will be removed to the designated waste stockpile, enabling blasting of the exposed magnetite ore into the pit and the commencement of consistent ore delivery to the DMS JV plant’.

They also said the bench would also be extended so my guess would be they are already in production and probably ramping up to capacity as we speak, until they get the bigger mill where I believe they’ll open a second bench in order to meet demand.

So in short, I think we’ll get an update from them next week.

'This initial waste blast is expected to have exposed approximately 3,000 tons of unweathered magnetite ore, which will be subsequently blasted and transported to the JV DMS processing plant for conversion into dense media separation (DMS) grade magnetite.Over the coming week, the overlying Gabro Norite waste rock will be removed to the designated waste stockpile, enabling blasting of the exposed magnetite ore into the pit and the commencement of consistent ore delivery to the DMS JV plant.

Lapon Mining is targeting production ramp-up to 20,000 tons of unweathered magnetite ore per month'.

With an additional larger ball mill being acquired as they cannot produce enough to meet demand, I find it hard to comprehend your comment this is just 'hype and spin', especially with photographic evidence to back up their statements.

Investors may well be disillusioned from previous management's broken promises but in my opinion this is now very real. They will be in production, it will generate substantial revenue and positive cash flow and results of this will be announced in the very near future .

I for one firmly believe this is substantially undervalued and it will rerate accordingly. I'm very much looking forward to the next two quarters and beyond.

I agree. An excellent medium and long term hold.

Many thanks Duster. Certainly confirms my view that the Mcap should be well in excess of 50 million.

HT if you didn't have a lower intellect than a shoelace you'd realise with patient one still alive and well efficacy is looking very promising.

Imagine a grown man still sulking years after Vlad blocked him on Twitter. Grow up you imbecile.

I have a question to the LTH's here. As you'll have far more knowledge than I do, what's your revenue projection for Ironveld moving forward?

My understanding is that they're looking to process 20,000 tons a month, but I don't know if that volume increases with the new bigger mill they are acquiring?

And although the iron ore price is falling due to China's economic woes I'm unsure of the premium Ironveld would get through selling iron powder?

Anyway, at the volume I anticipate, and with a 50% stake in the JV, at the lowest price point, I still have them generating revenues of £1m per month, probably with a margin of 50%+ in the not too distant future.

Does this seem right to you? Any input would be appreciated as I believe they're substantially undervalued at the moment, especially as I believe the plant on its own has an insurance valuation of £28m.

Thanks in advance.

Offler the cost of CAR-T varies greatly depending on the disease, the effectiveness and competitive landscape. Each hospital and medical institution would do a cost benefit analysis for a one time treatment, or multiple products against long term treatment and care given to each patient before deciding whether CAR-T was an appropriate way forward.

CAR-T will undoubtedly be a multi billion dollar market but you're right in the sense it will be restricted to advanced medical markets such as north america, the UK, China and a few others, with cost a predominant factor.

The NHS in the UK are positive towards CAR-T with therapy averaging around £280,000 a patient although they have negotiated substantial discounts with a couple of suppliers down to around £41,000 a patient. However, not relevant to Hemogenyx at the moment as they're only seeking approval in America.

Costs in America appear to range from $360,000 per patient to $500,000. It's important to note the vast majority of the cost is not for the product but for the hospital. From memory I believe Penn put the cost to the Company of manufacturing the product was around $100,000. With Trumps antics on health care you may well be right that less people will be covered by their medical insurance and will unfortunately die rather than be treated.

You made a very wise decision to wait before investing in Hemogenyx, unlike myself and many others that jumped in far too early. Personally although I hold warrants I disposed of my shares once I realised that several placements would be required and after they placed at a ludicrous 40% discount. My personal view is to wait for them to treat four patients before looking to re-enter. I'm very bullish on the science but less so on their business acumen. After they've secured funding for four patients, have patient one passing six months of treatment I believe they'll issue (or the hospital will) a scientific paper outlining not only the safety but initial efficacy. At that stage I believe they'll secure substantial funding that'll take CAR-T through the clinical trial phases and secure working capital to progress both CDX and CBR.

Of course all the above is just my personal opinion and I could be wrong on everything, and often am. If I've called it all wrong and I miss out on getting back in I'll take my losses on the chin with no regrets.

I wish you luck with whatever you decide to do.

Might just be because shareholders asked for a meeting but interesting our JV partner Sable jumped 40% today.

Chief Executive Kris Andersson said: "I am very pleased with the progress being made on the ground. We are now entering a pivotal phase as we transition into revenue generation, with sales of our DMS-grade magnetite, under the existing offtake agreement with Sable Platinum Pty, expected to commence shortly.

"Encouragingly, demand for our material has exceeded expectations, with new enquiries and requests for product coming in on a consistent basis...The emerging opportunity to sell ore directly adds an exciting dimension to our revenue streams and further reinforces the international demand for vanadium, titanium, and iron.

"Over the coming months, we anticipate a fundamental shift in Ironveld's trajectory, from a development-stage company to a fully operational, revenue-generating business with positive cash flow."

Ironveld CEO, Kris Andersson, commented:

"Market demand for our DMS-grade magnetite both from within the South Africa market and from nearby export countries is exceeding our current processing capacity. We are therefore looking to ramp up processing capacity through the acquisition of an additional larger mill and associated equipment. In addition, demand is also emerging for unprocessed Run of Mine ore"

It's not a bad situation at all to be able to sell all you can make, and more. More revenue equals more profit.

Chief Executive Kris Andersson said: "I am very pleased with the progress being made on the ground. We are now entering a pivotal phase as we transition into revenue generation, with sales of our DMS-grade magnetite, under the existing offtake agreement with Sable Platinum Pty, expected to commence shortly.

"Encouragingly, demand for our material has exceeded expectations, with new enquiries and requests for product coming in on a consistent basis...The emerging opportunity to sell ore directly adds an exciting dimension to our revenue streams and further reinforces the international demand for vanadium, titanium, and iron.

"Over the coming months, we anticipate a fundamental shift in Ironveld's trajectory, from a development-stage company to a fully operational, revenue-generating business with positive cash flow."

With another £900k raised for a larger mill to meet demand and another furnace coming online shortly, Q3 looks to be a real inflection point.

It’s quite possible this will be multiples of today’s price by the end of the year and if progress is as expected it looks likely this will be taken out by a major. In my opinion anyway.

with another £900k raised to fund infrastructure to support bigger volumes and larger offtake agreements, i think this interview from a few months back rings true.

i believe they'll be not only revenue generating but extremely profitable in the near future.

'ironveld expects to achieve positive cash flow from february 2025 as it ramps up production from two operational furnaces, with a third anticipated to come online by september 2025. cash flows have the potential to “improve sharply” from february 2025, noted gibb, as throughput increases, efficiencies improve, and the third furnace comes onstream. the production output includes high-purity iron powder, vanadium ****, and titanium ****, with confirmed demand from international markets.

ironveld’s management remains confident about the prospects of becoming a key player in the specialised hpi market. co**** hpi currently commands a market price of $1,000–$1,200 per tonne, while fine water-atomised hpi can fetch up to $1,500 per tonne. by targeting the fine hpi market, the company is positioning itself as the only producer of this product in africa.

sustainable growth and future ambitions

in a forward-looking move, ironveld is exploring green energy solutions through a partnership with burnstar technologies, aiming to use hydrogen as a reductant in its operations. additionally, the company plans to commission a demonstration unit for fine hpi to secure long-term offtake agreements, potentially unlocking further funding opportunities.

on a final note, ironveld’s successful fundraising and operational advancements underline its commitment to delivering sustainable growth. with solid plans in place and the support of shareholders, the company is on track to realise its vision of becoming a leading supplier in the high-value metals market'.

I agree, definitely a buy. A little patience and I think we’ll all do very well here.

Looks grossly undervalued to me so bought myself 19.5m. Should be an interesting few months.

It seems some people get upset if you state an opinion that doesn't align with theirs, but that's their problem not mine and I'll continue to post regardless.

So after yesterday's meeting here's how I see things.

Patients one and two are both alive and well and it's highly likely we'll be getting an update on both next week, with a statement on patient three, who I continue to believe will get their treatment in the coming weeks.

But, of even more interest was two statements that were made yesterday. The first related to a potential grant for CAR-T that had been paused that is now active again. The second related to discussions Hemogenyx are having regarding CBR. Vlad appeared very optimistic a deal was in the offering and as its unlike Vlad to discuss these areas one would assume it'll be concluded soon.

I remain bullish and believe it's just a matter of time before Hemogenyx is valued appropriately based on their excellent scientific progress.

HT if that's your interpretation that's fine. Mine differs in that all Hemogenyx have said is that secondary endpoint data will be collected over time, which has nothing to do with data protection.

The reporting schedule remains the same, 28 days, 3 months, six months, yearly. You don't think secondary objectives including efficacy will be in the 3 month report, I do.

It'll be out very soon so we'll see who's right.

HT you are a very strange individual. Ever since being blocked by Vlad on Twitter you have done nothing but whine and moan, adding zero value to any discussion from any poster.

If you had researched you would know there are many patients waiting to receive treatment from Hemogenyx, and even more children and adolescents. All these individuals have exhausted every other treatment option and the cold hard fact is they'll die without it.

The treatment of patient three WILL be very soon and patient four will be within a fortnight of patient three surviving 28 days. That's the schedule.

Once Hemogenyx publish their efficacy data to complement their excellent safety statistics then investors will see a rerate. It's a very high probability this product candidate will be of great interest to multiple majors and Hemogenyx will take a substantial share of the projected $32bn CAR-T market.

But, whilst Hemogenyx are saving lives you just continue with your whining.Just be aware nobody cares what you think.